Bookmark Kaumudi Online  Bookmark this site  Editor@Kaumudi  |  Marketing  Print Advt rates  |  Calendar 2012        Go!    
 
 
March 01, Sunday 2015 9:52 AM       

       HEADLINES: Man dies in accident                                              No AIIMS for Kerala                                              Saritha‚Äôs videos: Probe not making any headway?                                              Rs 872 cr for Kochi Metro, Rs 161 cr for Rubber board                                              Panniyan criticised for his interest in football commentary                                              GDP in 2015-16 to be 8-8.5%; double-digit growth soon, says Jaitley                                              Govt announces new IIT, IIMs                                              Jaitley's speech peppered with digs at UPA rule                                              Govt to provide additional 1,000 crores to Nirbhaya Fund                                              Prominent Russian opposition figure Boris Nemtsov shot dead                                              Jihadi John had anger management issues: ex-teacher                                              New Zealand beat Australia in thriller, enter WC quarters                                              UAE all out for 102 against India                                              India beat UAE by nine wickets in World Cup                                              Kaumudi Facebook
       BUSINESS Next Article: SBI mulls selling bad assets to ARCs in Jan-Mar quarter  
       Ranbaxy recalls over 64,000 bottles of generic Lipitor in US
 
         Posted on :22:10:56 Mar 8, 2014
   
A A
       Last edited on:22:10:56 Mar 8, 2014
         Tags: Ranbaxy, Lipitor in US
 

NEW DELHI: Drug major Ranbaxy Laboratories has recalled over 64,000 bottles of Atorvastatin calcium tablets, a generic version of cholesterol-lowering drug Lipitor, after a complaint of wrong dosage.

The Indian firm, which is reeling under regulatory action from the US Food and Drug Administration (USFDA), recalled the drug after a complaint by a pharmacist who discovered a 20 mg tablet inside a sealed bottle of Atorvastatin 10 mg tablets.

"Ranbaxy Pharmaceuticals is conducting a voluntary recall in the US limited to two lots of Atorvastatin calcium tablets, 10 mg manufactured in India which expire in May 2014," it said in a statement.

The company, majority owned by Japan's Daiichi Sankyo, said it recalled the tablets "because of a remote possibility of the presence of a 20 mg Atorvastatin calcium tablet in a 10 mg bottle."

"This is the basis of the voluntary recall," it added.

To date, Ranbaxy has not received any product complaints related to these batches, the company said.

"Other lot numbers, package sizes and strengths are not affected by this recall. The recall is being conducted at the retail level," it added.

Ranbaxy is withdrawing the lots out of abundant caution, keeping the safety of patients in mind and with full knowledge of the USFDA, it said.

In January, the USFDA prohibited Ranbaxy from producing and distributing drugs for the American market from its Toansa facility in Punjab.

The Toansa plant catered to over 70 per cent of Ranbaxy's requirement for raw material used in medicine formulations. Toansa was the fourth Ranbaxy plant banned by the USFDA.

In September, the USFDA imposed an import alert on Ranbaxy's Mohali plant in Punjab for violating good manufacturing norms.

Ranbaxy's key facilities at Paonta Sahib in Himachal Pradesh and Dewas in Madhya Pradesh have been under a US import alert since 2008.

A A
       BUSINESS
Next Article: SBI mulls selling bad assets to ARCs in Jan-Mar quarter
 
 
BUSINESS HEADLINES
Volatile Sensex logs 1st Budget day gain in 4 yrs, up 141 pts  
Air India to get Rs.2,500 crore of fresh equity  
Commodity regulator FMC to be merged with Sebi: Jaitley  
Budget Highlights  
For every Re in govt kitty, 24 paise to come from borrowing  
Sensex closes 472 points up; capital goods stocks zoom  
Railway-linked stocks subdued after Prabhu's budget  
Essential item prices could go up due to rise in rail freight  
Rlys to hike train speed to reduce travel time between metros  
S&P now says India 'bright spot', ups GDP forecast  
Reform policies to determine India's credit profile: Moody's  
Mutual fund investors cannot buy or sell on Budget day  
LG, Samsung Mobiles top 2 trusted brands in India: Report  
Brokerages expect Budget to stay firm on fiscal consolidation  
HSBC's India headcount up by 1,000; US staff size down  
SpiceJet offers Holi discount scheme starting at Rs.1,699  
HSBC gets summons from Indian Tax Dept;fears significant fines  
Fiscal deficit, low income constrain India's rating: S&P  
SpiceJet to get 2nd tranche of Rs 400 cr by Wednesday  
'FDI insurance rules could have been simpler'  
Pre-budget expectations, lead FPIs to stage a come back  
India's gold imports may rise to 35-40 tonnes in February  
Infy, Wipro, TCS eye robotics, driverless cars for next round of growth  
SpiceJet shares soar 17% on CCI nod for capital infusion plan  
Coal block auctions in India see aggressive bidding  
 
Is the budget presented by Arun Jaitley a balanced one?
Yes
 
No
 
Don't Know
 
 
 
Home Kerala India World Business Sports Sci&Tech Education Automobile CityNews Movies Environment Letters 
© Copyright keralakaumudi Online 2011  |  Reproduction in whole or in part without written permission is prohibited.
Head Office Address: Kaumudi Buildings, Pettah P.O, Trivandrum - 695024, India.
Online queries talk to Deepu Sasidharan, + 91 98472 38959 or Email deepu[at]kaumudi.com
Customer Service -Advertisement Disclaimer Statement   |  Copyright Policy